Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279201 · ClinicalTrials.gov registry record · Phase 4
The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 2,091
- Enrollment target
NCT00279201 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 2,091 participants.
The verdict
NCT00279201, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2,091 participants
- Enrollment target
Study Summary
This study will compare insulin lispro low mixture \[LM\] and insulin glargine both in combination with the patient's oral diabetes medicines, for their ability to control blood sugar in patients with type 2 diabetes and compare insulin lispro LM to insulin glargine with regard to the length of time that the overall blood sugar can be controlled. This study will also determine whether the safety of insulin lispro LM and any side effects that might be associated with it are different from those observed with insulin glargine, both in combination with the patient's oral diabetes medications. The addendum study (Intensification Addendum) will compare how different insulin treatments work to control blood sugar in patients whose diabetes could not be controlled by either insulin lispro LM or insulin glargine.
Interventions
- DRUG Insulin glargine
- DRUG Lispro
- DRUG Lispro Low Mix
- DRUG Lispro Mid Mix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,091 participants |
| Start Date | 2005-12 |
| Est. Completion | 2009-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00279201
The ClinicalTrials.gov registry entry for NCT00279201 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 2,091 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Insulin glargine is the first listed.
NCT00279201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00279201 about?
NCT00279201 is a clinical study titled "The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)". This study will compare insulin lispro low mixture \[LM\] and insulin glargine both in combination with the patient's oral diabetes medicines, for their ability to control blood sugar in patients with type 2 diabetes and compare insulin lispro LM to insulin glargine with regard to the length of time...
What is the current status of trial NCT00279201?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,091 participants. The study started on 2005-12. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00279201?
The interventions under investigation include: Insulin glargine (DRUG), Lispro (DRUG), Lispro Low Mix (DRUG), Lispro Mid Mix (DRUG).
Who is sponsoring clinical trial NCT00279201?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.